Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Luvadaxistat (Primary)
- Indications Cerebellar ataxia; Schizophrenia
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 13 Sep 2016 Status changed from suspended to recruiting.
- 16 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.
- 16 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.